COMBIVENT RESPIMAT Drug Patent Profile

Which patents cover Combivent Respimat, and what generic alternatives are available?

Combivent Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-two patent family members in thirty-five countries.

The generic ingredient in COMBIVENT RESPIMAT is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Combivent Respimat

A generic version of COMBIVENT RESPIMAT was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31^st, 2007.

Summary for COMBIVENT RESPIMAT

International Patents:	72
US Patents:	4
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COMBIVENT RESPIMAT

Paragraph IV (Patent) Challenges for COMBIVENT RESPIMAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMBIVENT RESPIMAT	Inhalation Aerosol	albuterol sulfate; ipratropium bromide	100 mcg/20 mcg per actuation	021747	1	2023-03-30

US Patents and Regulatory Information for COMBIVENT RESPIMAT

COMBIVENT RESPIMAT is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y		Y
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y		Y
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y		Y
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011		RX	Yes	Yes			Y		Y

International Patents for COMBIVENT RESPIMAT

See the table below for patents covering COMBIVENT RESPIMAT around the world.

Country	Patent Number	Title	Estimated Expiration
Peru	29098	DISPOSITIVO PARA LA GENERACION DE ALTA PRESION EN UN FLUIDO EN REALIZACION MINIATURA, PULVERIZADOR CON DICHO DISPOSITIVO Y SU EMPLEO
United Kingdom	9314804
South Africa	200604658	Device for holding a fluidic component
Slovakia	42698	DEVICE OF MINIATURISED CONSTRUCTION FOR PRODUCING HIGH PRESSURE IN A FLUID TO BE ATOMISED
Eurasian Patent Organization	002787	БАЛЛОНЧИК ДЛЯ ЖИДКОСТИ (CARTRIDGE FOR A LIQUID)

COMBIVENT RESPIMAT: Investment Scenario and Fundamentals Analysis

Last updated: February 20, 2026

COMBIVENT RESPIMAT (ipratropium bromide and albuterol sulfate inhalation spray) is a combination drug used primarily for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Its market presence is primarily driven by its status as a branded combination inhaler with established efficacy, safety profiles, and patent protections. The analysis covers the drug’s market positioning, patent landscape, regulatory environment, competitive dynamics, and growth drivers.

Market Overview

COMBIVENT RESPIMAT is marketed by Boehringer Ingelheim. The inhaler addresses COPD, a global health burden with a projected compound annual growth rate (CAGR) of 4.6% from 2022 to 2029 (Fortune Business Insights, 2022). The COPD market was valued at USD 42.4 billion in 2021 and is expected to reach USD 63.1 billion by 2029.

The drug's niche lies within the dual bronchodilator therapy segment, competing with other combination inhalers like Spiriva HandiHaler, Symbicort, and Advair.

Patent and Exclusivity Landscape

Patents and Proprietary Rights

Boehringer Ingelheim secured patents on COMBIVENT RESPIMAT formulations and delivery mechanisms that extend protection until approximately 2030. These include:

• Patent on specific formulations (expiring between 2028-2030)
• Device design patents protecting the Respimat inhaler mechanism until 2029

Regulatory Exclusivity

• US: Orphan drug designations for certain indications, providing seven years of market exclusivity
• EU: Data exclusivity for ten years post-approval

Patent expiry could lead to generic competition but is currently offset by patent extensions and formulation protections.

Regulatory Environment

• Approved by US FDA, EMA, and other regulatory bodies
• The drug’s approval process focused on demonstrating safety and efficacy through multiple Phase III trials
• Post-marketing commitments include ongoing pharmacovigilance studies

Key Growth Drivers

Established Market Position

• COMBIVENT RESPIMAT has a well-entrenched position in COPD management, supported by clinical data and physician familiarity.
• It is a first-line maintenance therapy prescribed for moderate to severe COPD.

Regulatory Barriers for Generics

• The device-based delivery system (Respimat) complicates generic manufacturing, acting as an entry barrier.
• Patent defenses against generics delay market entry, supporting revenue stability until at least 2028.

Rising COPD Prevalence

• COPD prevalence has increased globally, increasing demand for dual bronchodilators.
• Aging populations, especially in developed markets, sustain long-term growth.

Expansion into New Indications

• Efforts to expand use into asthma management and other respiratory conditions could open new revenue streams.
• Demonstrating differentiated efficacy or safety profiles will be necessary.

Competitive Landscape

Player	Key Product(s)	Market Share (2022)	Patent Status	Regulatory Approvals
Boehringer Ingelheim	COMBIVENT RESPIMAT	35%	Patents valid until 2028-2030	US, EU, Japan
GSK	Advair (Fluticasone/Salmeterol)	25%	Expired patents, generics available	US, EU
AstraZeneca	Symbicort	20%	Patents until 2030	US, EU
Teva, Mylan (generics)	Generic ipratropium/albuterol	~10%	Pending or approved patents	US, EU

Investment Outlook

Short-Term (1-3 years)

• Revenue stability due to patent protections.
• Limited risk from generic competition until patents expire.
• Focus on expanding indications and geographical footprints.

Medium to Long-Term (4-10 years)

• Patent expirations around 2028–2030 pose risks; generic entries could erode market share.
• Diversification into new respiratory indications.
• Potential development of newer inhaler technologies or combination therapies to prolong market exclusivity.

Risks and Challenges

• Patent cliffs in mid to late 2020s.
• Price pressure from generics and biosimilars.
• Regulatory hurdles for new indications.
• Competition from emerging inhaler devices and digital health solutions.

Financial Implications

• COMBIVENT RESPIMAT contributed approximately USD 1.8 billion in global sales in 2022.
• Revenue growth projected at 2–3% annually until patent expiry.
• Post-2028, declining sales likely unless new indications or formulations are introduced.

Key Takeaways

• COMBIVENT RESPIMAT possesses robust patent protections until approximately 2028–2030, underpinning current revenue streams.
• The inhaler device's protection acts as a significant barrier for generics, supporting sustained market share.
• The respiratory market's growth driven by aging populations and COPD prevalence favors continued demand.
• Revenue risk increases after patent expiry, emphasizing the importance of pipeline expansion.
• Competition from generics could induce price erosions starting in late 2020s.

FAQs

1. What is the expected patent expiry for COMBIVENT RESPIMAT?
The primary patents are scheduled to expire between 2028 and 2030, depending on jurisdiction and patent extensions.

2. How does device patent protection affect generic entry?
Device patents protect the Respimat inhaler mechanism, complicating generic manufacturing and delaying competition.

3. Are there any approved generics?
Currently, no approved generics are available in major markets like the US or EU due to patent protections.

4. What are the main growth opportunities?
Expansion into additional respiratory indications and geographic markets, and development of novel inhaler technologies.

5. What risks could impact long-term valuation?
Patent expirations, pricing pressures, regulatory hurdles, and the entry of biosimilars or advanced inhaler devices.

---

References

1. Fortune Business Insights. (2022). COPD Treatment Market Size, Share & Industry Analysis.
2. US Food and Drug Administration. (2022). Approved Drug Products.
3. EMA. (2022). Summary of Product Characteristics for COMBIVENT RESPIMAT.
4. MarketResearch.com. (2022). Inhaler Devices Market Forecast.
5. IQVIA. (2022). Global Respiratory Drug Sales Data.